A PYMNTS Company

FTC final order issued for Perrigo’s acquisition of Paddock Labs

By  |  June 26, 2012

The Federal Trade Commission has issued a modified final order settling charges related to Perrigo’s acquisition of Paddock Laboratories. The FTC alleged that the deal would have reduced the number of manufacturers for ammonium lactate cream and lotion, ciclopirox shampoo, and promethazine suppositories. These products are used for conditions such as dry skin and motion sickness. The acquisition would have also eliminated future competition for two generic testosterone gel products used as anti-inflammatories.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    To resolve the FTC’s charges, Perrigo and Paddock agreed to sell the six generic drugs to Watson Pharmaceuticals.

    Full content: FTC Press Release

     

    Related content: 2025: Reverse-Payment Settlements Unleashed

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.